Skip to main content

3 Result(s)

within Mojtaba Ghadiany Remove this filter

and

  1. Article

    Open Access

    Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

    Abolghasem Allahyari, Ali Ehsanpour, Behrouz Najafi, Nafseh Ansarinejad… in BMC Cancer (2022)

    Download PDF (675 KB) View Article

  2. Article

    Open Access

    Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

    Breast cancer is the most frequently diagnosed cancer and the leading reason for cancer-related death among women. Neoadjuvant treatment with dual-HER2 (human epidermal growth factor receptor 2) blockade has s...

    Abolghasem Allahyari, Ali Ehsanpour, Behrouz Najafi, Nafiseh Ansarinejad… in BMC Cancer (2022)

    Download PDF (816 KB) View Article

  3. No Access

    Article

    Modified Irinotecan Plus Cisplatin and Dexamethasone (ICD) Combination Chemotherapy as Salvage Chemotherapy for Patients with Relapsed/Refractory Diffuse Large Cell Lymphoma

    About 50 % of patients with diffuse large cell lymphoma are candidate for salvage chemotherapy followed by bone marrow transplantation in the selected patients. In the current study we evaluated modified ICD (...

    Mojtaba Ghadiany, Mohammad Foratyazdi… in Indian Journal of Hematology and Blood Tra… (2014)